United Therapeutics Corporation $UTHR Shares Sold by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 79.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,000 shares of the biotechnology company’s stock after selling 7,962 shares during the period. Integrated Wealth Concepts LLC’s holdings in United Therapeutics were worth $617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. SVB Wealth LLC acquired a new position in shares of United Therapeutics in the first quarter valued at about $32,000. Sound Income Strategies LLC acquired a new position in United Therapeutics during the first quarter valued at $49,000. State of Wyoming acquired a new position in United Therapeutics during the fourth quarter valued at $62,000. Brooklyn Investment Group lifted its position in United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the period. Finally, WPG Advisers LLC acquired a new position in United Therapeutics during the first quarter valued at $60,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Up 0.0%

Shares of UTHR opened at $405.02 on Friday. The firm’s fifty day moving average is $318.53 and its two-hundred day moving average is $307.56. The stock has a market cap of $18.27 billion, a PE ratio of 15.81, a price-to-earnings-growth ratio of 6.17 and a beta of 0.62. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $436.95.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. During the same period in the prior year, the business posted $5.85 earnings per share. The business’s quarterly revenue was up 11.7% on a year-over-year basis. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 8,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $398.55, for a total value of $3,188,400.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company’s stock, valued at $51,811.50. This represents a 98.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $385.21, for a total value of $4,237,310.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $14,168,409.01. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 128,816 shares of company stock valued at $45,836,113 in the last ninety days. 10.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on UTHR shares. Jefferies Financial Group raised their target price on United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Bank of America raised their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. UBS Group raised their target price on United Therapeutics from $415.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, September 4th. Morgan Stanley dropped their target price on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Finally, HC Wainwright raised their target price on United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Friday, September 5th. Nine research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $438.85.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.